Background: Menopause symptoms may be distressing especially when they appear at a time when women are expected to play significant responsibilities in society. Numerous biological systems are influenced by the hormonal changes that start during the menopausal transition. This review attempts to decipher the complex relationship between obesity, menopause, and depression citing some recent longitudinal and cross-sectional studies. Additionally, this study provides a summary of the different phytoestrogens, their sources, and probable mechanisms of action in addition to available therapeutic alternatives. Methodology: For this review purpose the authors have gone through a vast number of articles from various scientific databases like PubMed, Google Scholar, and Web of Science. Results: It is becoming clear that the physiological basis for these menopausal symptoms is complicated and connected to estrogen deficiency, but not alone. Other hormones like FSH, LH, progesterone, and inhibin B are the major ones that are both directly and indirectly responsible for most of the menopausal symptoms Numerous longitudinal and cross-sectional studies have found a direct relationship between the incidence of menopause and depression as well as obesity. Phytoestrogens like stilbene, lignans, isoflavone, and coumestan have been reported to be the alternatives to synthetic estrogen with lesser side effects as reported in various studies. Conclusion: The complex relationship between depression, menopause, and obesity presents a complex obstacle to women's health and overall well-being. There might be a lot of promising prospects for revolutionary advancements in women's health during the menopausal stage in the future. Promising drug development that targets not just one but also the three conditions -obesity, menopause, and depression - as well as more thorough research are needed to improve the healthcare system for women who suffer from these conditions.

In recent years, tyrosine kinase inhibitors (TKIs) have emerged as a promising class of drugs for cancer treatment, targeting specific cell signalling pathways. Pyrazolines, with their unique structure and versatile chemistry, have attracted significant attention among organic and medicinal chemists. They exhibit remarkable TKI activity, leading to their exploration of cancer chemotherapy. This review highlights recent advancements, including patents, approved drugs, and compounds in clinical trials, focusing on structure-activity relationships (SAR) within the pyrazoline ring and its derivatives as TKIs. The objective is to design molecules with high efficacy in inhibiting tyrosine kinases while minimizing toxicity, offering the potential for improved cancer treatment outcomes. Ongoing research demonstrates the scientific community's dedication to unlocking the potential of pyrazolines for more efficient cancer therapies.